Guardant Health (NASDAQ:GH) CEO Amirali Talasaz Sells 143,028 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 143,028 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total value of $21,674,463.12. Following the completion of the sale, the chief executive officer directly owned 1,881,336 shares in the company, valued at $285,097,657.44. This trade represents a 7.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Friday, June 26th, Amirali Talasaz sold 116,972 shares of Guardant Health stock. The stock was sold at an average price of $150.79, for a total value of $17,638,207.88.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The shares were sold at an average price of $109.89, for a total transaction of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The stock was sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Price Performance

Shares of GH opened at $150.03 on Wednesday. The business has a fifty day moving average of $115.18 and a 200 day moving average of $104.71. The firm has a market capitalization of $19.89 billion, a P/E ratio of -44.26 and a beta of 1.61. Guardant Health, Inc. has a one year low of $40.35 and a one year high of $153.95.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GH. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Evercore raised shares of Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, June 2nd. TD Cowen restated a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. JPMorgan Chase & Co. lifted their target price on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, The Goldman Sachs Group assumed coverage on Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Guardant Health has an average rating of “Buy” and a consensus target price of $144.82.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. V Square Quantitative Management LLC bought a new position in Guardant Health during the 4th quarter worth about $27,000. Chesapeake Asset Management LLC bought a new position in shares of Guardant Health during the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Guardant Health during the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC bought a new position in Guardant Health in the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC lifted its holdings in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.